Epilepsy Market


Epilepsy


As per the Epilepsy foundation, approximately 3.4 million people live with epilepsy in the United States, and over 150,000 new cases are diagnosed each year.
Among the European countries, the United Kingdom had the highest diagnosed Epileptic prevalent population with 443,603 cases, followed by Germany, with Spain accounting for the lowest Epileptic prevalence.

Epilepsy Therapeutic Market

The current Epilepsy treatment includes a combination of medications, diet therapy, and surgery. The type of drugs or therapies prescribed to Epileptic patient depends on the severity of the case.
The commonly used epilepsy treatment therapy is Anti-Epileptic Medications (AEDs). The early treatment choice for almost all patients with multiple seizures is AEDs. The medications effectively prevent and control the seizures.

Anticonvulsant therapy is also considered after two unprovoked epileptic seizures. The medication prescribed by the medical practitioner could be monotherapy or a combinational therapy including two or more products as a medication.

According to DelveInsight’s studies, the Anti-Epileptic Medications (AEDs) are classified as Sodium Channel Modulators, GammaAminobutyric Acid (GABA) Receptor Modulator, Calcium Channel Blockers, Receptor Blockers, and others.

The current epilepsy therapies belong to these classes amongst which sodium channel modulators occupies the maximum share followed by calcium channel blockers, and GABA Receptor Modulators. The least used class involves calcium and sodium channel blocker and Cannabidiol.

Epilepsy Market

The total Epilepsy market size, as calculated by DelveInsight, was approximately USD 2,984 Million in 2017.
According to DelveInsight’s Epilepsy market analysis, the Epilepsy market size is expected to grow in the coming years. Moreover, the total Epilepsy market size is set to show an extensive growth at a CAGR rate of 8.85% for a study period of 2017-2028.

Expected launch of potential therapies may increase Epilepsy drug market size in the coming years. Attributed to an increase in the diagnosed Epilepsy prevalent population, better diagnostics tools and positive outcomes of the several drug candidates during the clinical trials, Epilepsy market is going to move forward.

Key companies advancing Epilepsy Market

Key Pharma players such as Marinus Pharmaceuticals, Sage Therapeutics, SK Biopharmaceuticals, UCB, Neurelis, Zogenix, Aquestive Therapeutics, INSYS Therapeutics, Engage Therapeutics, Zynerba Pharma, etc. are the potent Healthcare companies creating a significant positive shift in the Epilepsy Market Size.

Upcoming drugs advancing Epilepsy Market

Cenobamate (YKP3089), Fintepla (ZX008), Ganaxolone, Natalizumab, and NRP2945are some of the upcoming Epilpsy drugs that are going to grab the Epilepsy market share and advance quality of living of the Epileptic patient pool.

Comments

Post a Comment

Popular posts from this blog

Beta-thalassemia Market Poised for Significant Growth with Novel Therapies and Rising Prevalence

The Beta-thalassemia market is set to experience remarkable growth in the coming years, driven by the increasing prevalence of the condition and the anticipated launch of innovative therapies. Leading players in the pharmaceutical and biotech industries, including Acceleron Pharma, Agios Pharmaceuticals, Bluebird Bio, and CRISPR Therapeutics, are working diligently to address unmet medical needs and expand treatment options. Download our sample pages @ https://www.delveinsight.com/report-store/beta-thalassemia-market?utm_source=report&utm_medium=promotion&utm_campaign=kpr Market Dynamics and Key Drivers Beta-thalassemia, a hereditary blood disorder caused by mutations in the HBB gene, results in reduced or absent synthesis of beta-globin chains in hemoglobin. This condition affects millions worldwide, with significant prevalence in regions such as the United States, Europe, and Asia. Recent advancements in diagnostics and a heightened focus on genetic counseling have contribute...
Read more

Growth of the Candidemia Market: Drivers, Developments, and Future Outlook (2024-2034)

Candidemia , a bloodstream infection caused by Candida species, poses significant health challenges, particularly among individuals with weakened immune systems. The global candidemia market is projected to experience a compound annual growth rate (CAGR) of 3.16% from 2024 to 2034. citeturn0search0 Market Drivers: Increasing Incidence: The rising number of immunocompromised patients, including those with HIV/AIDS, cancer, or organ transplants, has led to a higher prevalence of candidemia. Advancements in Diagnostics: The adoption of advanced diagnostic techniques, such as molecular assays and biomarker identification, facilitates swift and accurate detection of candidemia, enabling timely intervention and improved patient outcomes. Innovative Therapeutics: The development of novel antifungal medications and immune-based therapies offers enhanced efficacy and reduced adverse effects, contributing to market growth. To know more about candidemia market drivers, visit https://www.delvei...
Read more

Unlocking the Facts: C-Met Mutated Non-Small Cell Lung Cancer Epidemiology, Market Trends, and Leading Players

What is C-Met Mutated Non-small Cell Lung Cancer ? C-Met (also known as MET) is a gene that codes for a protein called the "hepatocyte growth factor receptor" (HGFR) or c-Met receptor. This receptor plays a crucial role in regulating cell growth, survival, migration, and invasion. When the c-Met gene is mutated, it can lead to the abnormal activation of signaling pathways that promote cancer development and progression. How is C-Met Mutated Non-small Cell Lung Cancer epidemiology segmented? C-Met Mutated Non-small Cell Lung Cancer epidemiology is segmented as C-Met Mutated Non-small Cell Lung Cancer Total Incident Cases, Age-specific C-Met Mutated Non-small Cell Lung Cancer cases, Gender-specific C-Met Mutated Non-small Cell Lung Cancer Cases, Stage-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, Type-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, and Total Treated C-Met Mutated Non-small Cell Lung Cancer Cases. What is the C-Met Mutated...
Read more